Discovery and Discussion Archive
December 2:
How a long forgotten virus could help us solve the antibiotics crisis
Viruses have a bad reputation – but some of them could one day save your life, says biotech entrepreneur Alexander Belcredi. In this fascinating talk, he introduces us to phages, naturally-occurring viruses that hunt and kill harmful bacteria with deadly precision and shows how these once forgotten organisms could provide new hope against the growing threat of antibiotic resistant superbugs. Coordinator: Dave Nelson. Moderator: Susan Eisman.
Alexander Belcredi studies how viruses can help in the fight against superbugs. He has been working in the pharmaceutical space for over a decade. He spent nine years at BCG where he was part of the global health care team, focusing on pharma and medtech. While at BCG, Belcredi became acutely aware of the urgent need to develop alternatives to antibiotics and was fascinated by the role that phage therapy can play. In 2017, he co-founded PhagoMed Biopharma GmbH, a biotech company developing phage-based pharmaceuticals to treat bacterial infections, where he is now the CEO. Belcredi holds an MA in Modern History and Economics from the University of St. Andrews as well as an MBA from INSEAD.
How a long forgotten virus could help us solve the antibiotics crisis
Viruses have a bad reputation – but some of them could one day save your life, says biotech entrepreneur Alexander Belcredi. In this fascinating talk, he introduces us to phages, naturally-occurring viruses that hunt and kill harmful bacteria with deadly precision and shows how these once forgotten organisms could provide new hope against the growing threat of antibiotic resistant superbugs. Coordinator: Dave Nelson. Moderator: Susan Eisman.
Alexander Belcredi studies how viruses can help in the fight against superbugs. He has been working in the pharmaceutical space for over a decade. He spent nine years at BCG where he was part of the global health care team, focusing on pharma and medtech. While at BCG, Belcredi became acutely aware of the urgent need to develop alternatives to antibiotics and was fascinated by the role that phage therapy can play. In 2017, he co-founded PhagoMed Biopharma GmbH, a biotech company developing phage-based pharmaceuticals to treat bacterial infections, where he is now the CEO. Belcredi holds an MA in Modern History and Economics from the University of St. Andrews as well as an MBA from INSEAD.
